Quality of life

Atlanta Neuroscience Foundation's World Neuroscience Day Conference Unveils a Dynamic Agenda Focused on AI, Health Equity, and Advocacy

Retrieved on: 
Tuesday, April 9, 2024
Mindfulness, Health, Conference, Exercise, Health equity, Education, Patient, Knowledge, AI, Neuroscience, Quality of life, Medicine, DSM-IV codes, Artificial intelligence, Nursing

World Neuroscience Day Conference will showcase the transformative impact of AI on diagnostics, treatment, and patient care.

Key Points: 
  • World Neuroscience Day Conference will showcase the transformative impact of AI on diagnostics, treatment, and patient care.
  • Acknowledging the importance of health equity, World Neuroscience Day Conference places a spotlight on the urgent need for accessible and inclusive neurological care.
  • Understanding that a holistic approach is crucial for overall well-being, World Neuroscience Day Conference incorporates health and wellness sessions into its agenda.
  • Join us on Saturday, May 4 to be part of this transformative celebration of World Neuroscience Day Conference.

Valeos Welcomes Dr. Stuart Sweet to Board of Directors

Retrieved on: 
Tuesday, April 9, 2024
American Express, Advisory Committee, Transplant, Organ transplantation, St. Louis Children's Hospital, GM, Information technology, Medicine, Entrepreneurship, CPO, Patient, SVP, CISO, Research, Organ, Human services, Doctor of Philosophy, Lung transplantation, MD, Quality of life, Health policy, Former, Hospital, Author, Ecosystem, OPTN, Government, Pediatrics, Dentistry

WASHINGTON, April 9, 2024 /PRNewswire/ -- Valeos, a 501(c)(3) nonprofit organization designed to improve organ transplant outcomes for patients and organ donors through data collaboration, today announced the appointment of Dr. Stuart C. Sweet, MD, PhD to its Board of Directors. Dr. Sweet is the W. McKim Marriott Professor of Pediatrics at Washington University in St. Louis, MO, and served as the 2016-2017 Board President of the Organ Procurement and Transplantation Network (OPTN), the U.S. national transplant system. Dr. Sweet spent more than two decades as the medical director of the pediatric lung transplant program at Washington University School of Medicine in St. Louis and St. Louis Children's Hospital, focusing clinically on pediatric lung transplantation and gaining expertise in organ allocation, clinical outcomes, health policy and the role of information technology in medicine.

Key Points: 
  • "I am honored to join the exceptional team at Valeos and continue my dedication to advancing the U.S. organ transplant system," said Dr. Sweet.
  • "We're excited to welcome Dr. Sweet to our Board of Directors.
  • This announcement follows an exciting year for Valeos, which saw its first appointments to its Board of Directors and Advisory Committee this past January.
  • With the backing of leading figures in healthcare, technology and government, Valeos is committed to building the world's largest de-identified transplant data sandbox.

Remission Medical Partners with Sterling Urgent Care to Expand Access to Rheumatology Services

Retrieved on: 
Tuesday, April 9, 2024
Diagnosis, Arthralgia, Patient, Medicine, Cardiology, Partnership, Rheumatism, PRO, Quality of life, Sterling, LLM, Arthritis, CDC, Region, Work, Human, Hospital

RICHMOND, Va., April 9, 2024 /PRNewswire/ -- Remission Medical announced a partnership with clinical innovator Sterling Urgent Care, to make access to Rheumatology treatment far more convenient across four states: Idaho, Utah, Wyoming and Montana.

Key Points: 
  • Remission Medical is a national virtual clinic offering diagnosis and longitudinal care in Rheumatology, powered by video visits and a technology platform focused on escalation avoidance.
  • According to Sterling Urgent Care spokesperson Dan Kenning, with 21 locations across four states, Sterling goes beyond typical urgent care.
  • They offer advanced primary care in specialties like cardiology, pulmonology, and now rheumatology, prioritizing swift and accurate diagnosis and treatment.
  • Sterling also leads in affordable healthcare with unique membership programs for individuals and businesses, aiming to provide quality care to those without access.

GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors

Retrieved on: 
Tuesday, April 9, 2024
RCT, Radiation, Brain, Completion, Progression-free survival, Risk, Patient, Lung, SRT, Neoplasm, Research, Indiana University, Breast, Doctor of Philosophy, MD, Quality of life, Trial of the century, Clinical trial, Melanoma, Recurrence, FDA, Craniotomy, Randomized controlled trial, Medical imaging

TEMPE, Ariz., April 9, 2024 /PRNewswire/ -- GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the lives of patients with brain tumors, today announced it has enrolled the 100th patient in its ROADS clinical study. ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).

Key Points: 
  • ROADS, or Radiation One and Done Study, is the randomized control trial (RCT) designed to compare FDA-cleared GammaTile with stereotactic radiotherapy (SRT).
  • Patients enrolled in the ROADS clinical trial are randomized into two treatment groups following craniotomy with brain metastasis tumor removal: GammaTile implant at the time of surgery versus post-operative SRT.
  • Enrollment in the Phase 3 trial has now surpassed half of the 180 planned patients.
  • Our dedication to the ROADS trial is fueled by our mission to furnish the highest caliber of clinical evidence through randomized trial research.

New Campaign Highlights How Certain Jobs Can Increase a Person's Risk for Lung Disease

Retrieved on: 
Tuesday, April 9, 2024
Pneumonia, Emphysema, Bronchitis, Disease, Tobacco, Agriculture, Risk, Urinary tract infection, Spirometry, Fatigue, Smoke, Quality of life, Sputum, Dust, Mucus, Smoking, Wheeze, American Lung Association, COPD, Air pollution, Workplace, Phlegm, Ageing, Mining, Nursing

CHICAGO, April 9, 2024 /PRNewswire/ -- Chronic obstructive pulmonary disease (COPD) impacts 11.7 million people living in the U.S. While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD. To help people identify workplace risk factors and encourage them to speak with their healthcare provider if they are experiencing symptoms, the American Lung Association is launching a campaign to raise awareness for occupational COPD. 

Key Points: 
  • While smoking is a significant risk factor for the disease, long-term exposure to dust, chemicals, fumes and vapors from the workplace may also lead to COPD.
  • COPD, which includes chronic bronchitis and emphysema, is a long-term lung disease that makes it hard to breathe.
  • Many workplaces may expose workers to risk factors for COPD, but the leading job types that increase risk for chronic lung disease include agriculture, mining and manufacturing.
  • Early treatment of a chronic lung disease, including reducing the exposure, can help lead to better health outcomes.

Ping An receives Low Risk ESG rating from Sustainalytics Still #1 in Mainland China's insurance sector

Retrieved on: 
Tuesday, April 9, 2024
Professional, Health, NBV, Certification, Risk management, Insurance, Risk, ESG, Ethics, Research, Female, Quality of life, Ping'an, Confidentiality, Ecosystem, HKEX, Privacy, ISO

HONG KONG and SHANGHAI, April 9, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318 / 82318; SSE: 601318) has again received a "Low Risk" ESG Risk Rating from Sustainalytics, ranked first in Mainland China's insurance sector.

Key Points: 
  • HONG KONG and SHANGHAI, April 9, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318 / 82318; SSE: 601318) has again received a "Low Risk" ESG Risk Rating from Sustainalytics, ranked first in Mainland China's insurance sector.
  • With a risk rating score of 17, this is the second time Ping An received a "Low Risk" ESG Risk Rating, confirming the superb ESG risk management capability of the Group.
  • Sustainalytics is one of the world-leading ESG research institutions, it has developed ESG risk rating and assessment systems for various industries, to provide a comprehensive analysis of companies' exposure to industry-specific material ESG risks and their risk management capabilities.
  • Its ESG risk rating is divided into five levels, namely negligible risk (0-10 points), low risk (10-20 points), medium risk (20-30 points), high risk (30-40 points) and severe risk (40 points and above), with lower score means lower ESG risk.

American Lung Association and LUNGevity Foundation Announce $3 Million Research Partnership to Intercept Lung Cancer

Retrieved on: 
Tuesday, April 9, 2024
Boston University, Lung cancer, Enzyme, Disease, Health equity, Partnership, Patient, Research, Doctor of Philosophy, Helpline, MD, Quality of life, Protein, Master of Science, Clinical trial, Partial, Johnson & Johnson, Interventional oncology, American Lung Association, UCLA, Charity Navigator, Cancer, Estate (law), Medical imaging

In a collaborative effort to end this devastating disease, the American Lung Association and LUNGevity Foundation have joined forces to invest $3 million over the next three years in research aimed at intercepting lung cancer – catching precancerous cells and blocking them from turning into cancer cells.

Key Points: 
  • In a collaborative effort to end this devastating disease, the American Lung Association and LUNGevity Foundation have joined forces to invest $3 million over the next three years in research aimed at intercepting lung cancer – catching precancerous cells and blocking them from turning into cancer cells.
  • The partnership builds upon previous collaborations, including research funded by American Lung Association, LUNGevity Foundation and Stand Up To Cancer, which has yielded significant findings in lung cancer interception.
  • Through initiatives like the American Lung Association Research Institute Accelerator Program and the LUNGevity Early Lung Cancer Center , this partnership aims to accelerate progress in lung cancer interception research and pave the way for personalized treatments for patients.
  • LUNGevity, the nation's leading lung cancer organization, is transforming what it means to be diagnosed and live with lung cancer.

Ping An receives Low Risk ESG rating from Sustainalytics Still #1 in Mainland China's insurance sector

Retrieved on: 
Tuesday, April 9, 2024
Professional, Health, NBV, Certification, Risk management, Insurance, Risk, ESG, Ethics, Research, Female, Quality of life, Ping'an, Confidentiality, Ecosystem, HKEX, Privacy, ISO

HONG KONG and SHANGHAI, April 9, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318 / 82318; SSE: 601318) has again received a "Low Risk" ESG Risk Rating from Sustainalytics, ranked first in Mainland China's insurance sector.

Key Points: 
  • HONG KONG and SHANGHAI, April 9, 2024 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. (hereafter "Ping An", the "Company" or the "Group", HKEX: 2318 / 82318; SSE: 601318) has again received a "Low Risk" ESG Risk Rating from Sustainalytics, ranked first in Mainland China's insurance sector.
  • With a risk rating score of 17, this is the second time Ping An received a "Low Risk" ESG Risk Rating, confirming the superb ESG risk management capability of the Group.
  • Sustainalytics is one of the world-leading ESG research institutions, it has developed ESG risk rating and assessment systems for various industries, to provide a comprehensive analysis of companies' exposure to industry-specific material ESG risks and their risk management capabilities.
  • Its ESG risk rating is divided into five levels, namely negligible risk (0-10 points), low risk (10-20 points), medium risk (20-30 points), high risk (30-40 points) and severe risk (40 points and above), with lower score means lower ESG risk.

European Parliament Recognizes Essential Tremor as Official Disease in Ground-Breaking Declaration

Retrieved on: 
Tuesday, April 9, 2024
European Parliament, Myenteric plexus, Movement disorder, Environment, Disease, Social justice, Patient, DSM-IV codes, Joint Declaration, Hope, Quality of life, Parliament, Essential tremor, European, Geography, Insightec, Pharmaceutical industry

BRUSSELS, April 9, 2024 /PRNewswire/ -- The European Parliament, in collaboration with Insightec and patient advocacy groups, has taken a historic step forward in the healthcare realm by signing a Joint Declaration to officially recognize essential tremor as a disease. This monumental move promises to enhance the lives of millions who suffer from the most common movement disorder worldwide, affecting an estimated 54 million people.

Key Points: 
  • The Joint Declaration specifically calls for the following:
    The formal recognition of essential tremor as a distinct disease.
  • "Access to treatment options for essential tremor is a matter of equality and social justice," echoes Maarit Matjussi, chair of ScanShakers and chairwoman of the Finnish Essential Tremor Association.
  • "Signing this Joint Declaration, together with Members of the European Parliament and patient associations across Europe, is a pivotal milestone for Insightec and for people living with essential tremor across Europe.
  • Members of the European Parliament, Insightec, and patient groups are united in their commitment to ensuring equal therapy access and improving quality of life for all affected by this disease.

Texas Cardiac Arrhythmia Institute at St. David's Medical Center first in U.S. to use FDA-approved pulsed field ablation system

Retrieved on: 
Tuesday, April 9, 2024
Electrophysiology, St Davids, Atrial fibrillation, Arrhythmia, Patient, PFA, Medical Center, Quality of life, FDA, Food, Medical device

The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.

Key Points: 
  • The first procedure was performed by Andrea Natale, M.D., F.H.R.S., F.A.C.C., F.E.S.C., cardiac electrophysiologist and executive medical director of TCAI, and Amin Al-Ahmad, M.D., clinical cardiac electrophysiologist.
  • Dr. Natale and Dr. Al-Ahmad were two of 67 global operators to participate in the trial that led to FDA approval.
  • The novel PFA system delivers short-duration, high-energy electrical pulses to the cardiac tissue to destroy cells that cause irregular heart rhythms without using excess heat or cold.
  • "Our team is honored to have played a part in piloting this new era of global innovation for cardiac arrhythmia."